Lv5
1000 积分 2024-12-25 加入
KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications
8小时前
已完结
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction
1天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
2天前
已完结
Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child
2天前
已完结
Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview
2天前
已完结
Discovery of an Orally Bioavailable and Brain Penetrant Selective Estrogen Receptor Degrader
3天前
已完结
Spotlighting ER Degraders for HR+/HER2- Breast Cancer
5天前
已关闭
Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape
5天前
已完结
Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological Evaluation
5天前
已完结
Evolution of Structure-guided Drug Design Strategies Targeting Mutations in Codon 12 of KRAS
7天前
已完结
皖公网安备34019202002308
